腱障害の世界市場：2024年～2031年

概要

世界の腱障害市場は、2023年に2,152億6,000万米ドルに達し、2024～2031年の予測期間中にCAGR 4.2％で成長し、2031年には2,991億6,000万米ドルに達すると予測されています。

腱障害とは、痛み、腫れ、パフォーマンスの低下を特徴とする腱の変性と定義されます。腱障害とは、腱が痛み、可動域が制限されることです。腱炎よりも一般的な腱障害は、加齢、ストレス、怪我など様々なことが原因で起こります。

腱は、筋肉と骨をつなぐロープ状の組織です。腱鞘炎は、腱を傷つけたり使いすぎたりすると発症します。腱障害は慢性化することもあるが、安静と理学療法によって症状が改善する可能性が高いです。

市場力学：

促進要因

腱およびスポーツ関連の傷害の増加

世界の腱障害市場の需要は、複数の要因によって牽引されています。腱障害市場は、腱およびスポーツ関連傷害の発生率の増加によって牽引されています。この動向は、特にアスリートや高齢化社会における、腱炎を助長するスポーツ活動、職業的外傷、ライフスタイルの変化の増加に大きく起因しています。

腱障害の有病率は上昇傾向にあり、スポーツ選手が経験する腱関連の傷害は年間100万件を超え、スポーツ傷害のかなりの部分を占めているという報告もあります。この動向は、スポーツや身体活動への参加の増加によってさらに悪化しており、効果的な治療オプションに対する需要の高まりにつながっています。2023年9月にSage Journalsが発表したように、腱損傷は、使い過ぎ、遺伝的素因、断裂、加齢などに起因する一般的な臨床問題です。世界中で年間3,000万件以上の腱損傷が発生しています。

同様に、2023年、全米安全評議会は、スポーツやレクリエーション用具による負傷で370万人が救急部で治療を受けたと発表しました。同じ情報源によると、2022年にはスポーツやレクリエーションによる負傷が12％増加すると報告されており、活動的な人々の間で腱炎のリスクが高まっていることが浮き彫りになっています。スポーツ・レクリエーションによる傷害は2023年に2％増加

さらに、この市場成長を促進するであろう腱鞘炎の治療への投資やより多くの焦点などの業界戦略の主要プレーヤー。例えば、2023年2月、グラスゴー大学からスピンアウトした腱疾患に特化したCauseway Therapeutics社は、リード化合物であるTenoMIRaの外側上顆炎（テニス肘）を対象とした国際第2相臨床試験を実施するため、投資家から875万ポンドを調達しました。

抑制要因

高額な治療費、薬剤に伴うリスクと毒性、人々の認識不足、限られた有効な治療オプション、規制上の課題などの要因が市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 腱およびスポーツ関連傷害の増加
    • 技術の進歩
  • 抑制要因
    • 高い治療費
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析

第6章 症状タイプ別

• アキレス腱炎
• 膝蓋腱炎
• 腱板腱炎
• 棘上筋腱炎
• その他の症状

第7章 治療別

• 薬剤タイプ
  • 非ステロイド性抗炎症薬
  • コルチコステロイド注射
• 装具、スプリント、ブレース
• その他

第8章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第11章 企業プロファイル

• Zimmer Biomet
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• 3M
• Stryker
• Smith+Nephew
• Ossur
• Merck & Co., Inc.
• Pfizer Inc
• GSK plc
• Johnson & Johnson Services, Inc.
• Abbott

第12章 付録

Overview

The global tendinopathy market reached US$ 215.26 billion in 2023 and is expected to reach US$ 299.16 billion by 2031 growing with a CAGR of 4.2% during the forecast period 2024-2031.

Tendinopathy is defined as tendon degeneration characterized by pain, swelling, and impaired performance. Tendinopathy is when a tendon becomes painful and has a limited range of motion. More common than tendonitis, tendinopathy can be caused by many things, like aging, stress, or injury.

Tendons are rope-like tissues that connect your muscles to your bones. Tendinopathy can develop when you injure or overuse a tendon. Although tendinopathy can become chronic, rest and physical therapy will likely improve symptoms.

Market Dynamics: Drivers

Increasing incidence of tendon and sports-related injuries

The demand for the global tendinopathy market is driven by multiple factors. The tendinopathy market is driven by an increasing incidence of tendon and sports-related injuries. This trend is largely attributed to a rise in sports activities, occupational injuries, and lifestyle changes that contribute to tendonitis, particularly among athletes and the aging population.

The prevalence of tendinopathy is rising, with reports indicating that athletes experience over a million tendon-related injuries annually, accounting for a significant portion of sports injuries. This trend is further exacerbated by the growing participation in sports and physical activities, leading to a higher demand for effective treatment options. As per Sage Journals publication in September 2023, tendon injuries are a common clinical problem that results from overuse, genetic predisposition, tears, or aging. More than 30 million tendon injuries occur annually worldwide.

Similarly, in 2023, the National Safety Council, stated that 3.7 million people were treated in emergency departments for injuries involving sports and recreational equipment. The same source, reported a 12% increase in sports and recreational injuries in 2022, highlighting the growing risk of tendonitis among active individuals The activities most frequently associated with injuries are exercise, cycling, and basketball. Sports and recreational injuries increase by 2% in 2023.

Moreover, key players in the industry strategies such as investments and more focus on the treatment of tendinopathy that would propel this market growth. For instance, in February 2023, Causeway Therapeutics, a University of Glasgow spin-out specializing in tendon disease raised £8.75 million from investors to conduct an international Phase 2 clinical trial of its lead compound, TenoMIRa in lateral epicondylitis (tennis elbow).

Also, in October 2021, Mayo Clinic Physical Medicine and Rehabilitation specialists Jeffrey S. Brault, D.O., and Jane Konidis, M.D., discuss two minimally invasive treatments for carpal tunnel syndrome and tendinopathy. New approaches to carpal tunnel release and treatment of tendinopathy.

Restraints

Factors such as high treatment costs, risk & toxicity associated with the drugs, lack of awareness among people, limited effective treatment options, and regulatory challenges are expected to hamper the market.

Segment Analysis

The global tendinopathy market is segmented based on condition type, treatment, distribution channels, and region.

The achilles tendinitis segment accounted for approximately 43.3% of the global tendinopathy market share

The achilles tendinitis segment is expected to hold the largest market share over the forecast period. The rise in sports activities, particularly among younger populations, has led to a corresponding increase in Achilles tendinitis cases. As more individuals engage in high-impact sports, the risk of developing this condition rises significantly driving this segment growth in the market.

Treatment modalities for Achilles tendinitis have evolved, with non-invasive options such as physical therapy, shockwave therapy, and regenerative therapies like platelet-rich plasma (PRP) injections gaining popularity. These treatments are preferred due to their effectiveness and lower recovery times compared to surgical options help to drive this market growth.

Moreover, key players in the industry more focus on research studies, investments in tendinopathy treatment, and key developments propel this segment in the market. For instance, in July 2022, a recent study in Physical Therapy in Sport found significant differences in strength and other fitness factors in those with Achilles tendinopathy compared to those without the condition. In addition to seeing a physical therapist to address Achilles pain, experts suggest focusing on calf-strengthening exercises, assessing your running schedule, and doing cross-training activities.

Similarly, in January 2023, NIH funded Penn Medicine's Achilles tendon research center for nearly $8M. The new Penn Achilles Tendinopathy Center of Research Translation seeks to build insights that lead to better treatment of Achilles tendon injuries.

Also, in July 2023, the Isokinetic Football Medicine Conference held May 25-27 in London revealed significant improvement in professional athletes with Achilles tendon injuries using a treatment of bio-inductive and multi-fractioned hyaluronic acid (HA) injections.

Geographical Analysis

North America accounted for approximately 42.8% of the global tendinopathy market share

North America region is expected to hold the largest market share over the forecast period owing to the high incidence of sports & occupational injuries driving this market growth in the region. According to the Science Direct in 2024, every year, there are more than 32 million acute and chronic tendon and ligament injuries that occur in the United States.

Moreover, the rising incidence of an aging population, well-established healthcare infrastructure, government initiatives such as awareness programs, and key player investments would drive this market growth. For instance, in January 2023, Zimmer Biomet Holdings, Inc. announced that it had reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 million at closing and up to an additional $120 million subject to achieving future regulatory and commercial milestones over three years.

In addition, a major number of key player's presence and product launches & approvals would propel this market growth in this region. For instance, in May 2021, Pendopharm launched SportVis, the first and only hyaluronic acid injection treatment that is clinically demonstrated and approved by Health Canada to relieve pain and restore function in damaged tendons and ligaments.

Also, in September 2021, Stryker introduced the new Citrelock Tendon Fixation Device System, which is designed to enable fixation without causing damage to the tendon during placement. The new system consists of a tendon thread with a resorbable technology called Citregen.

Market Segmentation

By Condition Type

• Achilles Tendinitis
• Patellar Tendinitis
• Rotator Cuff Tendinitis
• Supraspinatus Tendonitis
• Other Conditions

By Treatment

• Drug Type
  • NSAIDs
  • Corticosteroid Injections
• Orthotics, Splints and Braces
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • The rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the tendinopathy market include Zimmer Biomet, 3M, Stryker, Smith+Nephew, Ossur, Merck & Co., Inc., Pfizer Inc., GSK plc., Johnson & Johnson Services, Inc., and Abbott among others.

Key Developments

• In November 2022, Camber Pharmaceuticals launched generic Naprosyn. It is used to relieve pain from various conditions such as headaches, muscle aches, tendonitis, dental pain, and menstrual cramps.
• In May 2022, CoNextions Inc. announced the first patient treated with CoNextions TR tendon repair system, a revolutionary tendon repair implant.
• In April 2022, Boehringer Ingelheim launched RenuTend a new stem cell therapy to improve the healing of tendon and suspensory ligament injuries in horses.
• In July 2021, Ossur launched the new Rebound Post-Op Elbow Brace, a non-invasive, lightweight adjustable brace with intuitive design features intended to optimize the fitting experience for clinicians as well as ease-of-use for patients who are recovering from severe elbow injury or surgical procedures.

Why Purchase the Report?

• To visualize the global tendinopathy market segmentation based on condition type, treatment, distribution channels, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the tendinopathy market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global tendinopathy market report would provide approximately 62 tables, 56 figures, and 183 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Condition Type
• 3.2. Snippet by Treatment
• 3.3. Snippet by Distribution Channels
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Incidence of Tendon and Sports-related Injuries
    • 4.1.1.2. Growing Technological Advancements
  • 4.1.2. Restraints
    • 4.1.2.1. High Treatment Costs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. By Condition Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
  • 6.1.2. Market Attractiveness Index, By Condition Type
• 6.2. Achilles Tendinitis *
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Patellar Tendinitis
• 6.4. Rotator Cuff Tendinitis
• 6.5. Supraspinatus Tendonitis
• 6.6. Other Conditions

7. By Treatment

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Market Attractiveness Index, By Treatment
• 7.2. Drug Type *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.2.3. NSAIDs
  • 7.2.4. Corticosteroid Injections
• 7.3. Orthotics, Splints and Braces
• 7.4. Others

8. By Distribution Channels

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 8.1.2. Market Attractiveness Index, By Distribution Channels
• 8.2. Hospital Pharmacies *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Retail Pharmacies
• 8.4. Online Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Condition Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Zimmer Biomet *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. 3M
• 11.3. Stryker
• 11.4. Smith+Nephew
• 11.5. Ossur
• 11.6. Merck & Co., Inc.
• 11.7. Pfizer Inc
• 11.8. GSK plc
• 11.9. Johnson & Johnson Services, Inc.
• 11.10. Abbott

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us